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investigators to assess long-term outcomes. Ultimately, 
this eﬀ ort will contribute to core treatment standards 
for watchful waiting. 
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Bevacizumab in newly diagnosed ovarian cancer
Several studies have assessed the activity of 
bevacizumab when added to chemotherapy in ovarian 
cancer. In Europe, bevacizumab is approved by the 
European Medicines Agency in combination with 
carboplatin and paclitaxel in newly diagnosed ovarian 
cancer, with carboplatin and gemcitabine in platinum-
sensitive relapse ovarian cancer, and with chemotherapy 
in platinum-resistant relapse ovarian cancer. In the 
USA, bevacizumab is approved by the Food and Drug 
Administration when combined with chemotherapy 
for platinum-resistant relapse ovarian cancer. These 
approvals were based on progression-free survival 
improvements, but so far no overall survival beneﬁ t 
has been noted with the addition of bevacizumab to 
chemotherapy in any overall study population.2–5 
In The Lancet Oncology, Amit Oza and colleagues1 report 
the mature overall survival data from ICON7, an open-
label randomised phase 3 trial comparing bevacizumab 
plus six 3-weekly cycles of carboplatin and paclitaxel 
chemotherapy followed by bevacizumab maintenance 
versus the carboplatin and paclitaxel chemotherapy 
regimen alone. The study participants were patients with 
newly diagnosed ovarian cancer following cytoreductive 
surgery or patients with advanced-stage disease who 
had no further surgery planned.1 The primary endpoint 
of this trial, progression-free survival, has been reported 
previously.2 Concordant with the results of GOG-218,3 
another  phase 3 trial comparing chemotherapy and 
bevacizumab versus chemotherapy alone in upfront 
therapy for ovarian cancer, progression-free survival 
was 21·8 months  with the addition of bevacizumab 
compared with 20·3 months with chemotherapy alone 
in the overall study, and 18·1 months versus 14·5 months 
in a predeﬁ ned high-risk population of patients with 
suboptimally cytoreduced stage III or stage IV disease.2 
ICON7 was also designed and powered to assess overall 
survival, for which the mature data are now reported. 
Oza and colleagues found no overall survival diﬀ erence 
with the addition of bevacizumab to chemotherapy in 
the overall study population (restricted mean survival 
44·6 months [95% CI 43·2–45·9] with standard 
chemotherapy vs 45·5 months [44·2–46·7] in the 
bevacizumab group). However, in a high-risk subset 
of 502 patients with inoperable or suboptimally 
cytoreduced stage III or stage IV disease, they did note 
an overall survival beneﬁ t, with a mean overall survival 
of 34·5 months (95% CI 32·0–37·0) in the chemotherapy 
alone group compared with 39·3 months (37·0–41·7) 
with the addition of bevacizumab (log-rank p=0·03). 
No overall survival beneﬁ t was recorded in any other 
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predeﬁ ned subgroups, including clear cell, early-stage 
high-grade, or low-grade serous tumours.
When considering the various treatment options 
available to patients with newly diagnosed ovarian 
cancer, improved overall survival is an important goal. 
Thus, the ﬁ ndings reported by Oza and colleagues raise 
the question of whether or not bevacizumab should be 
considered as ﬁ rst-line therapy for selected patients at 
high risk of recurrence. Notably, however, in a post-hoc 
exploratory analysis in GOG-218 of a similar population 
to that reported by Oza and colleagues (suboptimally 
cytoreduced stage III or stage IV disease), improvement 
in overall survival with bevacizumab was not signiﬁ cant, 
with median overall survival of 38·6 months on 
standard chemotherapy compared with 42·1 months 
with chemotherapy and bevacizumab (hazard ratio 
[HR] 0·86 95% CI 0·71–1·04; p=0·055).6
When we place these ﬁ ndings into clinical context, 
the diﬀ erent treatment options for patients with newly 
diagnosed advanced ovarian cancer should also be 
considered. Although ICON7 used a chemotherapy 
backbone of 3-weekly carboplatin and paclitaxel, the 
JGOG-3016 trial done by Katsumata and colleagues7 
reported a signiﬁ cant progression-free and overall survival 
beneﬁ t when they substituted weekly paclitaxel for every-
3-week paclitaxel. This beneﬁ t was most pronounced in 
suboptimally cytoreduced disease, with an increase in 
median overall survival from 33·5 months to 51·2 months 
(HR 0·75 [95% CI 0·57–0·97]; p=0·0027).7 GOG-262, which 
also compared carboplatin and weekly paclitaxel versus 
carboplatin and paclitaxel every 3 weeks but allowed 
bevacizumab at the discretion of the investigator, showed 
no progression-free survival beneﬁ t when bevacizumab 
was added to weekly paclitaxel; the small percentage 
of patients who received weekly paclitaxel without 
bevacizumab seemed to have similar progression-free 
survival as those receiving bevacizumab.8 Although 
based on a small subset of patients (112 [16%] of 
692 patients), this ﬁ nding raises the possibility that either 
weekly paclitaxel or bevacizumab might be suﬃ  cient to 
achieve a progression-free survival beneﬁ t in patients 
with advanced-stage disease. Finally, in patients with 
advanced ovarian cancer, neoadjuvant chemotherapy and 
delayed interval cytoreductive surgery to reduce surgical 
morbidity has been established as a potential treatment 
option;9,10 however, the long half-life and side-eﬀ ect 
proﬁ le of bevacizumab means that the administration 
of this agent in the neoadjuvant setting is problematic. 
Therefore, clinicians now face the challenge of selecting 
the most appropriate ﬁ rst-line therapy for patients with 
advanced ovarian cancer. 
Although the results of ICON7 oﬀ er the tantalising 
possibility that a patient subgroup might derive an overall 
survival beneﬁ t from ﬁ rst-line bevacizumab, caution 
should be exercised when interpreting subset analyses, 
and additional questions remain unanswered regarding 
the use of bevacizumab in newly diagnosed ovarian cancer. 
Only a small proportion of patients in ICON7 received 
bevacizumab after disease recurrence, and therefore 
whether or not bevacizumab use in the recurrent setting 
could oﬀ set the overall survival beneﬁ ts recorded in this 
high-risk population remains unknown. Additional studies 
to understand the eﬀ ect of subsequent bevacizumab 
treatment on survival and to further identify and validate 
molecular markers of anti-angiogenic response will be 
important to better deﬁ ne our understanding of the role of 
bevacizumab therapy in ovarian cancer.
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Although various anti-VEGF therapies have been widely 
adopted as part of the treatment regimen for patients 
with metastatic colorectal cancer, a predictive biomarker 
for treatment eﬀ ectiveness has not yet been established.1,2 
RAS mutation analysis is a crucial component of 
diagnostic testing in assessing the role of anti-EGFR 
therapy;3 non-invasive approaches to the identiﬁ cation 
of these mutations are of great interest to physicians in 
view of the generally poor accessibility of archival tissue, 
which can be further complicated by the amount of tissue 
available, the remote storage location of the archival 
tissue, and storage conditions.  Despite these limitations, 
physicians often continue to attempt to retrieve the 
archival specimen—which can result in unnecessary 
treatment delays—to avoid an additional tissue biopsy or 
additional ﬁ nancial burden to the patient. For heavily pre-
treated patients who are seeking new treatment options, 
the timeframe for eﬀ ective treatment can be very narrow. 
In The Lancet Oncology, Josep Tabernero and colleagues 
have expanded their analysis4 of the placebo-controlled 
phase 3 trial of regorafenib for refractory metastatic 
colorectal cancer (CORRECT), the results of which 
were previously reported.5 In CORRECT, regorafenib, 
an oral multikinase inhibitor, was reported to improve 
overall survival beneﬁ t compared with placebo (6·4 vs 
5·0 months, hazard ratio [HR] 0·77, 95% CI 0·64–0·94, 
p=0·0052).5  In their exploratory analysis Tabernero 
and colleagues used several approaches to identify 
potential biomarkers associated with clinical outcome: 
mutation analysis for KRAS, BRAF, and PIK3CA by use 
of BEAMing (beads, emulsions, ampliﬁ cation, and 
magnetics) technology,  quantiﬁ cation of plasma 
circulating DNA  concentrations, and assessment of 
pretreatment plasma protein concentrations (high vs 
low) of 15 prespeciﬁ ed proteins of interest.   
Unfortunately, the investigators were unable to 
identify a speciﬁ c predictive marker for outcome 
after regorafenib treatment based on prespeciﬁ ed 
pretreatment plasma protein concentrations of interest. 
However, they did report that, not unexpectedly, 
pretreatment plasma circulating DNA concentrations 
were inversely related to overall survival (low vs high: 
HR 0·34, 95% CI 0·25–0·47). 
Distinct intrapatient tumour heterogeneity has 
previously been reported to potentially exist not only 
between the primary tumour and metastatic sites, 
but also between sites of metastatic disease, which 
might make mutation interpretation and treatment 
decisions more diﬃ  cult.6 One advantage of non-invasive 
circulating DNA for tumour mutation analysis is that 
physicians can use a real-time assessment of existing 
and acquired mutations associated with therapeutic 
resistance before conﬁ rmatory diagnostic imaging 
can be done or clinical progression occurs. Diﬀ erent 
approaches exist to sample circulating DNA, including 
PCR, Sanger sequencing, pyrosequencing, and BEAMing 
technology.7 BEAMing uses known hotspot mutations 
from speciﬁ ed genes to give a high sensitivity of less than 
0·1%, and is reportedly able to identify one mutant allele 
in 10 000 wild-type alleles.8 In the CORRECT exploratory 
analysis,  there was high concordance between matched 
plasma circulating DNA and tumour tissue for both 
KRAS and PIK3CA mutations assessed using BEAMing,9 
consistent with that reported in smaller studies. 
A small group of individuals with archival tumour tissue 
originally identiﬁ ed as KRAS wild-type were noted to 
have KRAS mutant tumour DNA in their circulating 
DNA sample, which suggested the development of an 
acquired mutation. Consequently, anti-EGFR therapy 
was no longer beneﬁ cial for these patients. In this 
scenario, circulating DNA removes the need for a tissue 
biopsy to conﬁ rm an acquired change in KRAS status.  
Although the biomarker analysis results from 
CORRECT are unlikely to change the basis of regorafenib 
treatment, these exploratory ﬁ ndings do show the 
potential usefulness of plasma circulating DNA as a 
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